Kazia Therapeutics
KZIA
8 hedge funds and large institutions have $472K invested in Kazia Therapeutics in 2020 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0.02% more ownership
Funds ownership: 0.01% → 0.03% (+0.02%)
0% more funds holding
Funds holding: 8 → 8 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
30% less capital invested
Capital invested by funds: $671K → $472K (-$199K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$2.18M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$28.1K |
| 3 |
Morgan Stanley
New York
|
+$23.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$6.34K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1K |
| 3 |
SPIA
Steward Partners Investment Advisory
New York
|
-$991 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $230K | +$23.4K | +118 | +8% |
|
|
2
Renaissance Technologies
New York
| $99K | -$6.34K | -32 | -4% |
|
|
HAG
3
HighPoint Advisor Group
Downers Grove,
Illinois
| $92K | – | – | – |
|
|
TW
4
Transform Wealth
Greenwood Village,
Colorado
| $26K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $25K | +$28.1K | +142 | +458% |
|
|
RE
6
RBC Europe
London,
United Kingdom
| $93 | – | – | – |
|
|
7
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$1K | -6 | Closed |
|
|
SPIA
8
Steward Partners Investment Advisory
New York
| – | -$991 | -5 | -42% |
|
|
AFM
9
Anson Funds Management
Dallas,
Texas
| – | +$2.18M | +11,000 | New |
|
KZIA Hedge Fund Activity: Q1 2020 in Review
8 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q1 2020, worth a combined $472K — down 30% from $671K a quarter earlier.
Fund positioning in KZIA was balanced in Q1 2020: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 2 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $2.18M. The largest seller was Renaissance Technologies, cutting an estimated $6.34K.
- 8 institutional investors held Kazia Therapeutics (KZIA) as of Q1 2020, unchanged from Q4 2019.
- Funds reported $472K of Kazia Therapeutics stock for Q1 2020, down 30% quarter-over-quarter.
- 1 fund opened new Kazia Therapeutics positions in Q1 2020 and 1 closed out, a net change of 0 holders.
- The largest Kazia Therapeutics buyer in Q1 2020 was Anson Funds Management, an estimated $2.18M added.
- The largest Kazia Therapeutics seller in Q1 2020 was Renaissance Technologies, an estimated $6.34K sold.
Based on aggregated 13F filings for Q1 2020.